Gynecologic Oncology | Specialty

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

Dr. Ferguson on Minimally Invasive Vs Open Surgery for Radical Hysterectomy in Cervical Cancer

December 17th 2019

Sarah Ferguson, MD, FRCSC, discusses the rationale to conduct a population-based cohort study comparing the efficacy of minimally invasive surgery versus open surgery for radical hysterectomy in women with cervical cancer.

Olaparib Approved in China for Frontline Maintenance in Ovarian Cancer

December 5th 2019

China’s National Medical Products Administration has granted marketing authorization for olaparib as a first-line maintenance treatment for adult patients with newly diagnosed advanced germline or somatic BRCA-mutated epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to frontline platinum-based chemotherapy.

UK Expands Olaparib Maintenance Indication in Ovarian Cancer

December 3rd 2019

The UK’s National Institute for Health and Care Excellence has approved olaparib for the maintenance treatment of adult patients with relapsed, platinum-sensitive, high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer whose disease responded to platinum-based chemotherapy and harbor BRCA1/2 mutations.

Recent Data Muddle Role of Secondary Surgery in Recurrent Ovarian Cancer

December 3rd 2019

Sarah Crafton, MD, discusses the role of secondary surgical cytoreduction in recurrent ovarian cancer.

A Society That Worries About Risks Should Consider Cancer Prevention

November 23rd 2019

When discussing the topic of vaccination to prevent serious childhood illness, an increasing number of individuals refuse to accept the unequivocally demonstrated value of this public health strategy despite the very low risk of harm.

Real-World Evidence Reassuring for PARP Inhibitor Use in Ovarian Cancer

November 22nd 2019

Floor J. Backes, MD, discusses subtle differences among PARP inhibitors that can help determine their optimal use in advanced ovarian cancer.

Combos Could Unlock Major Immunotherapy Benefits in Ovarian Cancer

November 22nd 2019

John Hays, MD, PhD, discusses ongoing research with immunotherapy in ovarian cancer, challenges with determining predictive biomarkers of response, and promising emerging modalities.

Expert Shares Insight on Evolution of Ovarian Cancer Therapeutics

November 21st 2019

Larry J. Copeland, MD, discusses how therapy for patients with ovarian cancer has evolved in recent years.

Dr. Salani Discusses Potential Treatment Modalities in Cervical Cancer

November 21st 2019

Ritu Salani, MD, discusses the potential of targeted therapy and immunotherapy in cervical cancer.

Gynecologic Cancer Research Thrives at The Ohio State University

November 21st 2019

Experts from The Ohio State University and Allegheny Health Network discuss the exciting research being conducted at their institutions.

Individualized Approach Imperative in Frontline Ovarian Cancer

November 20th 2019

Ritu Salani, MD, discusses the evolution of up-front chemotherapy, as well as the roles of primary debulking surgery and neoadjuvant chemotherapy in ovarian cancer.

O'Malley Highlights Pivotal Trials in Ovarian Cancer

November 19th 2019

David O’Malley, MD, discusses clinical trials in ovarian cancer and others under investigation.

Genetic Testing Is Suggested First Step Upon Ovarian Cancer Diagnosis

November 18th 2019

Leigha Senter, MS, LGC, discusses the current state of genetic testing for patients with ovarian cancer.

Dr. Leath on Agents Under Investigation in Cervical Cancer

November 15th 2019

Charles A. Leath III, MD, gynecologic oncologist at the University of Alabama at Birmingham, discusses agents under investigation in cervical cancer.

Dr. Coleman on Ongoing Research in Cervical Cancer

November 14th 2019

Robert L. Coleman, MD, FACOG, FACS, discusses ongoing research efforts in cervical cancer.

Dr. Backes on Safety Profile of Lenvatinib and Weekly Paclitaxel in Endometrial Cancer

November 12th 2019

Floor J. Backes, MD, discusses the safety profile from a phase I study looking at lenvatinib and weekly paclitaxel in women with recurrent endometrial cancer.

Dr. Yadav on Differences in Type 1 and Type 2 Uterine Cancer

November 12th 2019

Ghanshyam Yadav, MD, discusses the differences between type 1 and type 2 uterine cancer.

Dr. Coleman on Investigational Treatment Strategies in Cervical Cancer

November 8th 2019

Robert L. Coleman, MD, FACOG, FACS, professor and Ann Rife Cox Chair in Gynecology, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses investigational treatment strategies in cervical cancer.

Efforts Continue to Perfect PARPi Use in Ovarian Cancer

November 8th 2019

As PARP inhibitors have now moved into the frontline maintenance setting in ovarian cancer, researchers are now seeking to even further capitalize on use of these agents, including indications in treatment-naïve patients.

Dr. Leath on the Results of the GOG 240 Trial in Advanced Cervical Cancer

November 7th 2019

Charles A. Leath III MD, gynecologic oncologist at the University of Alabama at Birmingham, discusses results of the phase III GOG 240 trial in advanced cervical cancer.